DrugPatentWatch Database Preview
Tocilizumab - Biologic Drug Details
» See Plans and Pricing
Summary for tocilizumab
| Tradenames: | 1 |
| Patents: | 79 |
| Applicants: | 1 |
| BLAs: | 2 |
| Suppliers: see list | 1 |
| Recent Clinical Trials: | See clinical trials for tocilizumab |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for tocilizumab |
Recent Clinical Trials for tocilizumab
Identify potential brand extensions & biosimilar entrants
| Sponsor | Phase |
|---|---|
| The Swedish Research Council | Phase 4 |
| Vastra Gotaland Region | Phase 4 |
| Noordwest Ziekenhuisgroep | Phase 2 |
Recent Litigation for tocilizumab
Identify key patents and potential future biosimilar entrants
District Court Litigation
| Case Name | Date |
|---|---|
| Celgene Corporation v. Aurobindo Pharma Limited | 2018-07-06 |
| CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD. | 2018-06-28 |
| AMGEN INC v. SANDOZ INC. | 2018-06-26 |
See all tocilizumab litigation
PTAB Litigation
| Petitioner | Date |
|---|---|
| Crescendo Bioscience, Inc | 2017-04-12 |
Pharmacology for tocilizumab
| Mechanism of Action | Interleukin 6 Receptor Antagonists |
Patent Text Search: US Patents for tocilizumab
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Number | Approval Date | Patent No. | Assignee | Estimated Patent Expiration | Status | Orphan | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Warsaw Orthopedic, Inc. (N/A) | 2026-04-13 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Warsaw Orthopedic, Inc. (N/A) | 2039-02-26 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Chelsea Therapeutics, Inc. (Charlotte, NC) | 2024-09-08 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Hoffmann-La Roche Inc. (Nutley, NJ) | 2027-05-02 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Aegis Therapeutics LLC (San Diego, CA) | 2026-06-23 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Merck Sharp & Dohme Corp. (Rahway, NJ) | 2030-05-11 | RX | search | |
| Genentech | ACTEMRA | tocilizumab | INJECTABLE; INJECTION | 125276 | 001 | 2010-01-08 | Start Trial | Genentech, Inc. (South San Francisco, CA) Hoffmann-La Roche Inc. (Nutley, NJ) | 2030-11-08 | RX | search | |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Number | >Approval Date | >Patent No. | >Assignee | >Estimated Patent Expiration | >Status | >Orphan | >Source |
International Patents for tocilizumab
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2291678 | Start Trial |
| South Korea | 20170110167 | Start Trial |
| European Patent Office | 2475383 | Start Trial |
| European Patent Office | 3017303 | Start Trial |
| South Korea | 101495408 | Start Trial |
| Serbia | 54560 | Start Trial |
| China | 110248680 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for tocilizumab
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 20C/505 | Belgium | Start Trial | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| 2020505 | Lithuania | Start Trial | PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 90010-6 | Sweden | Start Trial | PRODUCT NAME: UPADACITINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/19/1404 20191218 |
| 2020000011 | Germany | Start Trial | PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 20191216 |
| 2020000000022 | Italy | Start Trial | PRODUCT NAME: UPADACITINIB IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(RINVOQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1404, 20191218 |
| 1035 | Netherlands | Start Trial | PRODUCT NAME: UPADACITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/19/1404 20191218 |
| C00149 | Luxembourg | Start Trial | PRODUCT NAME: UPADACITINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/19/1404 20191218 |
| >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
